[212Pb] VMT-α-NET
Phase 1Active 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroendocrine Tumors
Conditions
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
Trial Timeline
Nov 10, 2023 → Dec 31, 2027
NCT ID
NCT06148636About [212Pb] VMT-α-NET
[212Pb] VMT-α-NET is a phase 1 stage product being developed by Perspective Therapeutics for Neuroendocrine Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT06148636. Target conditions include Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06148636 | Phase 1 | Active |
Competing Products
20 competing products in Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |